

Vijay K Ramanan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/761762/publications.pdf>

Version: 2024-02-01

38
papers

1,023
citations

623734

14
h-index

454955

30
g-index

49
all docs

49
docs citations

49
times ranked

2369
citing authors

#	ARTICLE	IF	CITATIONS
1	Genetic studies of quantitative MCI and AD phenotypes in ADNI: Progress, opportunities, and plans. <i>Alzheimer's and Dementia</i> , 2015, 11, 792-814.	0.8	241
2	Pathway analysis of genomic data: concepts, methods, and prospects for future development. <i>Trends in Genetics</i> , 2012, 28, 323-332.	6.7	237
3	GWAS of longitudinal amyloid accumulation on ¹⁸ F-florbetapir PET in Alzheimer's disease implicates microglial activation gene <i>IL1RAP</i> . <i>Brain</i> , 2015, 138, 3076-3088.	7.6	117
4	Genome-wide pathway analysis of memory impairment in the Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort implicates gene candidates, canonical pathways, and networks. <i>Brain Imaging and Behavior</i> , 2012, 6, 634-648.	2.1	58
5	Predicting Short-term MCI-to-AD Progression Using Imaging, CSF, Genetic Factors, Cognitive Resilience, and Demographics. <i>Scientific Reports</i> , 2019, 9, 2235.	3.3	51
6	Association of Apolipoprotein E ε4, Educational Level, and Sex With Tau Deposition and Tau-Mediated Metabolic Dysfunction in Older Adults. <i>JAMA Network Open</i> , 2019, 2, e1913909.	5.9	41
7	Gene-based GWAS and biological pathway analysis of the resilience of executive functioning. <i>Brain Imaging and Behavior</i> , 2014, 8, 110-118.	2.1	33
8	Comprehensive Gene- and Pathway-Based Analysis of Depressive Symptoms in Older Adults. <i>Journal of Alzheimer's Disease</i> , 2015, 45, 1197-1206.	2.6	33
9	Statins and Brain Health: Alzheimer's Disease and Cerebrovascular Disease Biomarkers in Older Adults. <i>Journal of Alzheimer's Disease</i> , 2018, 65, 1345-1352.	2.6	23
10	<i>FASTKD2</i> and human memory: functional pathways and prospects for novel therapeutic target development for Alzheimer's disease and age-associated memory decline. <i>Pharmacogenomics</i> , 2015, 16, 429-432.	1.3	20
11	Genome-wide association study of language performance in Alzheimer's disease. <i>Brain and Language</i> , 2017, 172, 22-29.	1.6	20
12	Coping with brain amyloid: genetic heterogeneity and cognitive resilience to Alzheimer's pathophysiology. <i>Acta Neuropathologica Communications</i> , 2021, 9, 48.	5.2	18
13	Transient Epileptic Amnesia: A Treatable Cause of Spells Associated With Persistent Cognitive Symptoms. <i>Frontiers in Neurology</i> , 2019, 10, 939.	2.4	17
14	Subacute encephalitis with recovery in IgLON5 autoimmunity. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2018, 5, e485.	6.0	16
15	White matter damage due to vascular, tau, and TDP-43 pathologies and its relevance to cognition. <i>Acta Neuropathologica Communications</i> , 2022, 10, 16.	5.2	14
16	Genetic Influences on Plasma Homocysteine Levels in African Americans and Yoruba Nigerians. <i>Journal of Alzheimer's Disease</i> , 2016, 49, 991-1003.	2.6	12
17	Variants in <i>PPP2R2B</i> and <i>IGF2BP3</i> are associated with higher tau deposition. <i>Brain Communications</i> , 2020, 2, fcaa159.	3.3	12
18	<i>APOE</i> ε4 Allele Testing and Risk of Alzheimer Disease. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 484.	7.4	11

#	ARTICLE	IF	CITATIONS
19	Cerebral Amyloid Angiopathy Pathology and Its Association With Amyloid- β PET Signal. <i>Neurology</i> , 2021, 97, e1799-e1808.	1.1	10
20	Exploring common genetic contributors to neuroprotection from amyloid pathology. <i>Brain Communications</i> , 2022, 4, fca066.	3.3	10
21	Cerebral Amyloid Angiopathy Burden and Cerebral Microbleeds: Pathological Evidence for Distinct Phenotypes. <i>Journal of Alzheimer's Disease</i> , 2021, 81, 113-122.	2.6	8
22	Association Between Plasma Biomarkers of Amyloid, Tau, and Neurodegeneration with Cerebral Microbleeds. <i>Journal of Alzheimer's Disease</i> , 2022, 87, 1537-1547.	2.6	4
23	Promoting Well-being Among Neurology Residents: A Data-Driven Approach. <i>Mayo Clinic Proceedings Innovations, Quality & Outcomes</i> , 2020, 4, 469-474.	2.4	3
24	Tau polygenic risk scoring: a cost-effective aid for prognostic counseling in Alzheimer's disease. <i>Acta Neuropathologica</i> , 2022, 143, 571-583.	7.7	3
25	Genome-wide association study of tau-PET: Association of variant near NTNG2 with resistance to tau deposition. <i>Alzheimer's and Dementia</i> , 2020, 16, e044321.	0.8	2
26	<i>APOE</i> Allele Testing and Alzheimer Disease—Reply. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 2211.	7.4	2
27	Three cases of Creutzfeldt-Jakob disease presenting with a predominant dysexecutive syndrome. <i>Journal of Neurology</i> , 2022, 269, 4222-4228.	3.6	2
28	Polygenic Scores of Alzheimer's Disease Risk Genes Add Only Modestly to APOE in Explaining Variation in Amyloid PET Burden. <i>Journal of Alzheimer's Disease</i> , 2022, 88, 1615-1625.	2.6	2
29	O3-13-04: Genome-wide rare variant analysis identifies candidate genes significantly associated with composite scores for memory. , 2015, 11, P251-P252.		1
30	Longitudinally Increasing Elevated Asymmetric Flortaucipir Binding in a Cognitively Unimpaired Amyloid-Negative Older Individual. <i>Journal of Alzheimer's Disease</i> , 2021, , 1-6.	2.6	1
31	P3-024: NEXT-GENERATION SEQUENCING OF THE BCHE LOCUS IDENTIFIES A FUNCTIONAL SNP ASSOCIATED WITH ALZHEIMER'S DISEASE BIOMARKERS AND AGE OF ONSET. , 2014, 10, P636-P636.		0
32	P4-191: Gwas identifies gli3 as a novel gene for language deficits and cortical changes in older adults at-risk for Alzheimer's disease. , 2015, 11, P853-P853.		0
33	O4-05-01: Gwas of longitudinal amyloid PET identifies IL1RAP as a new potential Alzheimer's disease target. , 2015, 11, P277-P278.		0
34	P1-414: STATINS AND BRAIN HEALTH: MEDICATION EFFECTS ON NEUROIMAGING BIOMARKERS IN OLDER INDIVIDUALS. <i>Alzheimer's and Dementia</i> , 2018, 14, P463.	0.8	0
35	IC-059: <i>APOE</i> AND EDUCATION: EFFECTS ON REGIONAL TAU AND FDG METABOLISM IN OLDER ADULTS. <i>Alzheimer's and Dementia</i> , 2019, 15, P58.	0.8	0
36	CD33 , MEF2C , and SORL1 are associated with variability in macroscale functional brain architecture in AD. <i>Alzheimer's and Dementia</i> , 2020, 16, e046573.	0.8	0

#	ARTICLE	IF	CITATIONS
37	Dysexecutive Alzheimer's Disease with Lewy Body Disease Co-Pathology. Current Alzheimer Research, 2022, 19, 330-333.	1.4	0
38	Exercise and Brain Health. Neurology, 2022, 98, 825-826.	1.1	0